<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04434911</url>
  </required_header>
  <id_info>
    <org_study_id>PRECISE</org_study_id>
    <nct_id>NCT04434911</nct_id>
  </id_info>
  <brief_title>Precision Medicine Study on Cardiovascular Disease (PRECISE)</brief_title>
  <acronym>PRECISE</acronym>
  <official_title>Precision Medicine Study on Cardiovascular Disease (PRECISE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China National Center for Cardiovascular Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>China National Center for Cardiovascular Diseases</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiovascular diseases are the leading cause of death in China and have become a financial&#xD;
      burden on society under the traditional medical model. A new and sustainable medical model is&#xD;
      needed to solve this dilemma, for which precision medicine models have great potential.&#xD;
      Monogenic cardiovascular disease is the first field to be broken through in precision&#xD;
      medicine at this stage, and it is also the field where precision medicine is most likely to&#xD;
      be successfully transformed into clinical application, including genetic diagnosis, molecular&#xD;
      typing, risk stratification, genetic interruption and individualized treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, patients with monogenic cardiovascular disease are recruited prospectively&#xD;
      after informed consent was given. The investigator will collect the baseline clinical&#xD;
      characteristics of the patients at enrollment, including comprehensive physical examination,&#xD;
      laboratory testing of blood and urine, electrocardiography, 24-hour Holter, echocardiography,&#xD;
      MRI and other examinations if necessary. The specimens retained include blood, saliva, urine&#xD;
      and feces for all patients, and myocardium for patients receive cardio myectomy surgery .&#xD;
      Genetic testing will be performed to identify novel disease genes, genetic risk factors and&#xD;
      potential therapy targets.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 10, 2021</start_date>
  <completion_date type="Anticipated">October 10, 2030</completion_date>
  <primary_completion_date type="Anticipated">October 10, 2025</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>number of participants with cardiovascular deaths</measure>
    <time_frame>an average of 5 years</time_frame>
    <description>including sudden cardiac death and deaths due to heart failure and stroke.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>number of participants with all-cause death</measure>
    <time_frame>an average of 5 years.</time_frame>
    <description>deaths due to all cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of participants with heart failure</measure>
    <time_frame>an average of 5 years</time_frame>
    <description>progress to level III or IV in New York Heart Association class.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of participants with stroke</measure>
    <time_frame>an average of 5 years</time_frame>
    <description>including cerebral infraction and hemorrhage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of participants with malignant arrhythmia</measure>
    <time_frame>an average of 5 years</time_frame>
    <description>including ventricular fibrillation and ventricular tachycardia</description>
  </secondary_outcome>
  <enrollment type="Anticipated">20000</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Specimens retained include blood, saliva, urine, feces, and myocardium when the patients&#xD;
      receive cardio myectomy surgery.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with monogenic cardiovascular disease from multiple centers in China between&#xD;
        October 10, 2020 and October 10, 2025&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with monogenic cardiovascular diagnosed according current practice guideline.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who refuse to sign the informed consent or decline follow-up.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lei Song, MD. ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fuwai Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lei Song, MD.&amp;ph.D</last_name>
    <phone>86-13810532620</phone>
    <email>clinicalfw@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lei Song, MD.ph.D</last_name>
    <phone>86-18600197655</phone>
    <email>clinicalfw@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fuwai hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>June 15, 2020</study_first_submitted>
  <study_first_submitted_qc>June 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 17, 2020</study_first_posted>
  <last_update_submitted>March 7, 2021</last_update_submitted>
  <last_update_submitted_qc>March 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>China National Center for Cardiovascular Diseases</investigator_affiliation>
    <investigator_full_name>Lei.Song@NCCD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>monogenic cardiovascular disease</keyword>
  <keyword>clinical outcomes</keyword>
  <keyword>genomics</keyword>
  <keyword>genetic diagnosis</keyword>
  <keyword>risk stratification</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

